Daisy-30

Daisy-30

desogestrel + ethinylestradiol

Manufacturer:

Mylan Phils

Distributor:

Metro Drug
Concise Prescribing Info
Contents
Desogestrel 150 mcg, ethinylestradiol 30 mcg
Indications/Uses
Dosage/Direction for Use
1 tab daily at the same time (preferably in the evening) w/o interruption for 21 days, followed by a break of 7 tab-free days.
Administration
May be taken with or without food.
Contraindications
Hypersensitivity. Moderate to severe HTN. Hyperlipoproteinaemia. Arterial thrombosis present or in history (eg, MI, CVA). Presence of >1 risk factors for arterial disease. History of venous thromboembolism (VTE); family history of idiopathic VTE; other known risk factors for VTE. DM w/ vascular involvement. Cholelithiasis. Known or suspected estrogen-dependent tumours, endometrial hyperplasia; undiagnosed vag bleeding. SLE. Severe liver disease, cholestatic jaundice or hepatitis (viral or non-viral), if liver function tests failed to return normal or found normal 3 mth after the test. Rotor syndrome & Dubin-Johnson syndrome, hepatic cell tumours & porphyria. History during pregnancy or previous use of steroids of severe pruritis; pemphigoid gestationis, jaundice, manifestation/deterioration of otosclerosis. Pregnancy & lactation.
Special Precautions
Discontinue if there is presence of coagulation disorders, conditions associated w/ increased risk of circulatory disease eg, latent or overt cardiac failure, renal dysfunction, epilepsy, migraine, cholelithiasis; any risk factor for estrogen-dependent tumours, estrogen-sensitive gynaecological disorders eg, uterine fibromyomata & endometriosis; DM, severe depression, sickle cell haemoglobinopathy, abnormal liver function test. Increased risk of arterial, venous thrombotic & thromboembolic diseases eg, MI, stroke, DVT & pulmonary embolism. Discontinue in case of increase in frequency or severity of migraine during therapy. May promote growth of existing sex steroid dependent tumours. Risk of ovarian, endometrial, cervical & breast cancer. History of chloasma gravidarum; avoid exposure to sun or UV radiation in women w/ a tendency of chloasma. Use of steroids may influence the results of laboratory tests. Pregnancy & lactation.
Adverse Reactions
Cholestatic jaundice or cholelithiasis. Increased BP; intermenstrual bleeding, post-medication amenorrhoea, changes in cervical secretion, increased in size of uterine fibromyomata, aggravation of endometriosis & certain vag infections (eg, candidiasis). breast tenderness/pain/enlargement/secretion; nausea, vomiting, cholelithiasis, cholestatic jaundice; erythema nodosum, rash, chloasma; discomfort of the cornea if contact lenses are used; headache, migraine, mood changes, depression; fluid retention, change in body wt, reduced glucose tolerance.
Drug Interactions
Irregular cycles & reduced reliability in concomitant use w/ anticonvulsants, barbiturates, antibiotics (eg, tetracyclines, ampicillin, rifampicin, etc.), griseofulvin, St. John's wort, activated charcoal & certain laxatives. May diminish glucose tolerance & increase need for insulin or other antidiabetic drugs in diabetes.
MIMS Class
Oral Contraceptives
ATC Classification
G03AA09 - desogestrel and ethinylestradiol ; Belongs to the class of progestogens and estrogens in fixed combinations. Used as systemic contraceptives.
Presentation/Packing
Form
Daisy-30 tab
Packing/Price
21's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in